World's Top 15 Companies in Diabetes Drug In 2025 Watch List; Statistics Report (2024–2035)

Description

According to a research report published by Spherical Insights & Consulting, The Global Diabetes Drug Market Size is projected to Grow from USD 74.49 Billion in 2024 to USD 151.45 Billion by 2035, at a CAGR of 6.66% during the forecast period 2025–2035. The need for diabetes medications is rising as the disease's prevalence rises. Additionally, their demand is rising as a result of the government's initiatives and programs raising awareness.

 

Introduction

Diabetes is a long-term metabolic condition marked by elevated blood glucose levels that seriously harms the heart, blood vessels, kidneys, eyes, and neurological system. When the body becomes insulin resistant or produces insufficient amounts of insulin, type 2 diabetes results. In the Americas, diabetes affects 62 million individuals, most of whom reside in low- and middle-income nations.  Each year, diabetes is directly to blame for 284,049 deaths. Technological developments, increased acceptance rates in emerging nations, and a growth in the number of people with diabetes might all contribute to a more strong worldwide market. Moreover, higher rates of obesity, sedentary lifestyle adoption, and bad diet intake are predicted to raise the incidence of diabetes and support industry expansion. The growing number of people with diabetes, technological development, rising sales of new medications, and a rising rate of acceptance in developing nations are the main factors propelling the diabetes drugs market.

 

Key Market Trends:

Excessive sugar consumption increases the risk of developing diabetes.

Excess sugar consumption raises the risk of developing diabetes. Furthermore, developments in diabetes diagnosis technologies, such as portable glucometers, are driving the diabetes diagnostics market. A glucometer is a compact, portable device used mostly by diabetics to monitor blood glucose. Ascensia Diabetes Care, a global diabetes care company, got FDA certification for its implantable, next-generation Eversense E3 continuous glucose monitoring (CGM) device in February 2022. These guidelines, as well as continuous glucose monitoring (CGM) devices, aid in the diagnosis and treatment of diabetes. As a result, the availability of such improved glucose monitoring devices promotes market growth.

 

Technological improvement in diabetic therapy creates future potential.

Demand for these items is driven by technological developments in diabetes devices, such as the launch of high-end insulin pumps and pens. To capture a sizable portion of the market, top manufacturers concentrate on creating cutting-edge products and technological advancements.  In February 2019, Abbott and Novo Nordisk established a non-exclusive cooperation. It is anticipated that this partnership will contribute to the development of digital diabetes solutions. Through this agreement, Novo Nordisk's prefilled, durable linked pens will capture data that will be reflected in the digitally connected FreeStyle Libre system through the LibreView cloud-based system and the FreeStyle LibreLink mobile app. By combining technology, medical practitioners can examine insulin and glucose data at the same time, which could make managing diabetes easier.

 

Diabetes Drug Market Size & Statistics

The market for diabetes drug was estimated to be worth USD 74.49 billion in 2024.

The market is going to expand at a CAGR of 6.66% between 2025 and 2035.

The Global Diabetes Drug Market is anticipated to reach USD 151.45 billion by 2035.

North America is expected to generate the highest demand during the forecast period in the diabetes drug market

Europe is expected to grow the fastest during the forecast period in the diabetes drug market.

 

Regional growth and demand                               

Europe is expected to grow the fastest during the forecast period in the diabetes drug market. The need for diabetic medications is rising as the prevalence of diabetes in Europe rises. As a result, several companies are creating new medications to counteract these increasing occurrences. Therefore, all of these elements stimulate market expansion, as does government assistance.  The need for diabetes medications is rising as the disease's prevalence rises. Additionally, their demand is rising as a result of the government's initiatives and programs raising awareness. As a result, government financing and investments promote and expedite their production and development.

 

North America is expected to generate the highest demand during the forecast period in the diabetes drug market. The American Diabetes Association estimates that 1.4 million Americans receive a diabetes diagnosis annually. In Canada and the rest of North America, diabetes is one of the main causes of death. New medications are being created to give diabetes patients more treatment options because of the disease's progressive nature, rising incidence, and frequency.  More than half of the anti-diabetic market is currently made up of non-insulin procedures that are utilized as first-line treatments for people with type 2 diabetes. Two significant medication classes have entered this market in the past ten years: sodium-glucose cotransporter-2 inhibitors (SGLT-2) and DPP-4 inhibitors.

 

Top 15 Companies Leading the Diabetes Drug Market

1. Novo Nordisk A/S
2. Sanofi
3. Eli Lilly and Company
4. AstraZeneca
5. Boehringer Ingelheim
6. Merck & Co., Inc.
7. Pfizer Inc.
8. Johnson & Johnson
9. Novartis AG
10. Takeda Pharmaceutical Company Limited
11. Bristol-Myers Squibb
12. Biocon Limited
13. Teva Pharmaceutical Industries Ltd.
14. Mylan (Viatris Inc.)
15. Astellas Pharma Inc.

 

1. Novo Nordisk

Headquarters - Denmark

Novo Nordisk, a world pioneer in the development of diabetic medications with its headquarters located in Denmark, specializes in GLP-1 receptor agonists and insulin treatments. Its portfolio includes well-known medications that treat the problems of Type 2 diabetes and obesity, such as Rybelsus, Victoza, and Ozempic. The company has established industry standards with its innovations in combination medicines (Xultophy) and long-acting insulin (Tresiba). Novo Nordisk makes significant investments in R&D and digital health platforms in an effort to enhance patient outcomes. It accounted for the biggest portion of the global diabetes care market in 2024. Its dedication to sustainability, affordability, and tailored care serves to further solidify its market leadership in diabetic medications.

 

1. Sanofi

Headquarters – France

Sanofi, a prominent player in the diabetes medication industry, is headquartered in Paris, France, and provides a wide variety of insulin and non-insulin treatments. Its key blood glucose-controlling drugs, Apidra, Toujeo, and Lantus, are extensively used. In an effort to improve treatment effectiveness, Sanofi has also made investments in GLP-1 agonists and combination medicines. Strategic alliances, like its relationship with Verily Life Sciences, facilitate individualized diabetes care powered by AI. Sanofi's robust research pipeline and global presence establish it as a major pioneer in the treatment of chronic illnesses. The business keeps using patient support initiatives and digital platforms to increase access to diabetic drugs.

 

1. Eli Lilly

Headquarters – US

Eli Lilly, a US company based in Indiana, is a leader in the development of diabetes medications and is well-known for its insulin analogs and GLP-1 receptor agonists. Trulicity, Jardiance, and Humalog, which are frequently used for the treatment of Type 2 diabetes, are among its products. Mounjaro (tirzepatide), Lilly's newest innovation, has redefined treatment guidelines by demonstrating notable advantages for glycemic management and weight loss. The business uses AI and digital health solutions to enable remote monitoring and individualized care. Eli Lilly, which focuses on both efficacy and patient-centric solutions, is still a leading competitor in the diabetic medication industry due to its robust global presence and ambitious R&D strategy.

 

1. AstraZeneca

Headquarters - UK

AstraZeneca, a well-known biopharmaceutical firm in the diabetes medication market with its headquarters located in Cambridge, UK, offers cutting-edge treatments, including Bydureon and Farxiga. An SGLT2 inhibitor called Farxiga is frequently used to treat Type 2 diabetes and the cardiovascular problems that go along with it. Combination treatments and increasing access in developing markets are priorities for AstraZeneca. Its use of real-world data and digital platforms promotes better treatment results. The company is positioned as a strategic player in diabetes management due to its emphasis on integrated care models and metabolic health. AstraZeneca is still working with healthcare systems to make diabetes drugs more accessible and affordable.

 

1.  Boehringer Ingelheim

Headquarters - Germany

Germany-based Boehringer Ingelheim has a significant role in the market for diabetic drugs, especially with its oral drugs, such as Jardiance and Glyxambi. Co-developed with Eli Lilly, Jardiance is an SGLT2 inhibitor that has shown advantages for heart and kidney health in people with Type 2 diabetes. The business specializes in innovative pharmacological techniques and partnerships fueled by research. Boehringer's competitive edge is strengthened by its dedication to cardio-renal-metabolic care and its growing array of diabetic treatments. To enhance adherence and results, it also makes investments in patient education and digital health. Boehringer continues to be an important participant in the treatment of diabetes by placing a high priority on innovation and international collaborations.

 

Are you ready to discover more about the diabetes drug market?

The report provides an in-depth analysis of the leading companies operating in the global diabetes drug market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Novo Nordisk A/S

Business Overview

Company Snapshot

Products Overview

Company Market Share Analysis

Company Coverage Portfolio

Financial Analysis

Recent Developments

Merger and Acquisitions

SWOT Analysis

1. Sanofi
2. Eli Lilly and Company
3. AstraZeneca
4. Boehringer Ingelheim
5. Merck & Co., Inc.
6. Pfizer Inc.
7. Johnson & Johnson
8. Novartis AG
9. Others.

 

Conclusion

The market for diabetic medications is expanding steadily due to rising prevalence, rising public awareness, and a strong pipeline of cutting-edge treatments. Collaborations in technology, particularly in the areas of connected care devices and digital health, are enabling better diabetes control. In both wealthy and developing nations, government programs and growing healthcare expenditures are speeding up the uptake and accessibility of drugs. The sector is well-positioned to gain from strategic R&D and growing treatment alternatives, with North America leading in demand and Europe expected to grow at the highest rate. When taken as a whole, these elements highlight a dynamic and changing environment for producers of diabetic medications during the coming ten years.